Lamivudine/tenofovir

Lamivudine/tenofovir
Combination of
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Names
Trade namesCimduo, Temixys
Clinical data
Main usesPrevent and treat HIV/AIDS[1][2]
Side effectsHeadache, pain, diarrhea, rash, depression, liver problems, kidney problems, pancreatitis, osteoporosis, lactic acidosis, immune reconstitution syndrome[1][1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		By mouth
External links
AHFS/Drugs.comMonograph
MedlinePlusa618039
Legal
License data
Legal status

Lamivudine/tenofovir disoproxil (3TC/TDF), sold under the brand name Cimduo among others, is a combination medication used to prevent and treat HIV/AIDS.[1][2] It is taken by mouth.[1] It is used together with other medications in people weighing more than 35 kilograms (77 lb).[1]

Common side effects include headache, pain, diarrhea, rash, and depression.[1] Other side effects may include liver problems, kidney problems, pancreatitis, osteoporosis, lactic acidosis, and immune reconstitution syndrome.[1] In those who are also infected with hepatitis B, stopping use may worsen outcomes.[1] It contains lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) both reverse transcriptase inhibitors.[1]

The combination was approved for medical use in the United States in 2018.[1] It is also approved in a number of countries in Europe.[1] The lamivudine component was first approved in 1995.[4] It was added to the World Health Organization's List of Essential Medicines in 2021.[5][2] It is available in some areas as a generic medication.[4] In the United States it costs about 1,100 USD per month as of 2023.[6] Though the individual components cost about 140 USD per month if purchased separately.[7] It appears to work as well as emtricitabine/tenofovir but is less expensive.[4][8]

Medical uses

Dosage

It is taken as one pill once per day.[1] Each pill contains 300 mg of lamivudine and 300 mg of tenofovir.[1]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Archived from the original on 15 February 2020. Retrieved 26 March 2020.
  2. 1 2 3 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 27 March 2023. Retrieved 19 October 2023.
  3. ↑ "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Archived from the original on 14 February 2022. Retrieved 13 February 2022.
  4. 1 2 3 Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.
  5. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  6. ↑ "Cimduo". Retrieved 19 October 2023.
  7. ↑ Rosenberg, Tina. "H.I.V. Drugs Cost $75 in Africa, $39,000 in the U.S. Does It Matter?". New York Times. Archived from the original on 9 February 2023. Retrieved 19 October 2023.
  8. ↑ "HIV Prevention: What the TDF/3TC? The rationale and the evidence for TDF/3TC in PrEP". www.who.int. Archived from the original on 20 October 2023. Retrieved 19 October 2023.
Identifiers:
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.